Exhibit 99.2 Johnson & Johnson and subsidiaries Supplementary sales data (Unaudited; Dollars in Millions) SECOND QUARTER Percent Change | --- | --- | --- | --- | --- | --- | |---------------------------------------|---------|--------|-------|------------|----------| | Sales to customers by geographic area | 2024 | 2023 | Total | Operations | Currency | | U.S. | $12,569 | 11,657 | 7.8 % | 7.8 | — | | Europe | 5,214 | 5,131 | 1.6 | 3.4 | (1.8) | | Western Hemisphere excluding U.S. | 1,212 | 1,136 | 6.7 | 22.6 ...

Loading...Loading...Johnson & Johnson JNJ is reporting its second-quarter earnings on Wednesday. Wall Street expects $2.7 in EPS and $22.3 billion in revenues as the company reports before market hours.The stock is down 5.56% over the past year, -4.16% YTD.Let’s look at what the charts indicate for Johnson & Johnson stock and how the stock currently maps against Wall Street estimates.Johnson & Johnson Technical Setup Ahead Of Q2 Earnings Johnson & Johnson stock is exhibiting a strongly bullish trend, as its ...

Loading...Loading...Johnson & Johnson JNJ will release its second-quarter financial results, before the opening bell on Wednesday, July 17.Analysts expect the New Brunswick, New Jersey-based company to report quarterly earnings at $2.70 per share, up from $2.56 per share in the year-ago period. Johnson & Johnson is expected to post revenue of $22.29 billion, compared to $25.53 billion a year earlier, according to data from Benzinga Pro.Emergent BioSolutions Inc EBS, through its subsidiary Emergent Manufactu ...

GERMANY - 2024/02/16: In this photo illustration, a Johnson & Johnson logo seen displayed on a ... [+] tablet. (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesJohnson & Johnson stock (NYSE: JNJ) will report its Q2 2024 results on Wednesday, July 17. We expect the company to post revenue of $22.5 billion and earnings of $2.72 per share, broadly aligning with the consensus estimates of $22.4 billion and $2.71, respectively. J&J will likely ...

Johnson & Johnson (JNJ) will report its second-quarter 2024 earnings on Jul 17. The Zacks Consensus Estimate for second-quarter sales and earnings is pegged at $22.38 billion and $2.71 per share, respectively. Earnings estimates for JNJ have declined from $10.64 per share to $10.50 per share for 2024 and from $10.92 per share to $10.86 per share for 2025 over the past 60 days.JNJ Estimate MovementImage Source: Zacks Investment ResearchEarnings Surprise HistoryThe healthcare bellwether’s performance has been ...

SANTA ANA, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer ("NK") cell therapeutics, today announced the appointment of Dr. Marco Gottardis as a director and member of the Company's Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee, effective July 11, 2024. Dr. Got ...

They don't have the most exciting businesses, but they have a lot to offer nonetheless.Healthcare never sleeps. There is always demand for medical services, regardless of the state of the economy. Companies that offer these necessary goods and are innovative enough to keep up with the changing trends in the sector tend to last. That describes Johnson & Johnson (JNJ 0.12%) and Medtronic (MDT -0.15%) well. Both are among the largest healthcare companies in the world, have proven innovative abilities, and have ...

文章核心观点 - 2024年第二季度财报季已经全面展开,预计标普500指数将再次实现盈利增长[1] - 下周将有多家知名公司如Netflix、台积电和强生公司发布财报,值得关注[2] Netflix - Netflix的订阅者数量指标将是关键,公司将从2025年第一季度开始不再报告季度会员数[4] - 最新一季度Netflix的总订阅用户达到2.696亿,同比增长16%,连续4个季度超出预期[5] - Netflix的盈利能力和营收增长都有所改善,预计本季度每股收益将增长43%,收入增长17%[6] 台积电 - 受益于人工智能热潮,台积电股价今年已涨超80%,大幅跑赢大盘[9] - 本季度每股收益预计增长20%至1.37美元,收入预计增长5%至202亿美元,同比增29%[10] - 投资者对台积电未来增长前景乐观,估值有所扩张,但PEG仍在合理区间[11] - 台积电近期还宣布将派息提高10%,深受重视收益的投资者青睐[12] 强生公司 - 强生公司股价在过去3年中一直横盘整理,下跌4%,但盈利表现一直较为出色[13] - 本季度每股收益预计为2.71美元,较4月中旬的预期下调1%[15][17] - 收入预计同比下降12%至224亿美元[16]

The upcoming report from Johnson & Johnson (JNJ) is expected to reveal quarterly earnings of $2.71 per share, indicating a decline of 3.2% compared to the year-ago period. Analysts forecast revenues of $22.38 billion, representing a decrease of 12.3% year over year.Over the last 30 days, there has been a downward revision of 0.3% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the co ...

Recession-proof stocks offer investors a safe harbor to shield their portfolios from downside risk.The stock market has cooled off following its AI-powered surge for the last two years. While most experts have called for a soft economic landing, the looming possibility of a recession next year complicates the investing landscape. Hence, the focus is now more on resilient and operationally efficient companies that can hold their own during economic downturns.These businesses boast robust fundamentals thanks ...